ReviewTheScientificWorldJournal2014
Apathy in Alzheimer's disease: any effective treatment?
Review in TheScientificWorldJournal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Repetitive transcranial magnetic stimulation for apathy in mild cognitive impairment: A double-blind, randomized, sham-controlled, cross-over pilot study.Psychiatry research · 2018Trial
- GWAS links APOE to neuropsychiatric symptoms in mild cognitive impairment and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Understanding neuropsychiatric symptoms in Alzheimer's disease: challenges and advances in diagnosis and treatment.Frontiers in neuroscience · 2023Review
- Association Between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in the Treatment of Depression in Patients with Alzheimer's Disease.Journal of Alzheimer's disease reports · 2022Article
- Apathy: Neurobiology, Assessment and Treatment.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2021Article
- Apathy Antedating and Evolving With Dementia: A Case Report and Insights Into Apathy as a Network Dysfunction.Cureus · 2021Article
- Steps Towards Developing Effective Treatments for Neuropsychiatric Disturbances in Alzheimer's Disease: Insights From Preclinical Models, Clinical Data, and Future Directions.Frontiers in aging neuroscience · 2020Review
- Peptide YY Causes Apathy-Like Behavior via the Dopamine D2 Receptor in Repeated Water-Immersed Mice.Molecular neurobiology · 2018Article
- Apathy in Alzheimer's disease.Current opinion in behavioral sciences · 2018Review
- Article
- [Methylphenidate in a patient with Alzheimer's disease : Increase in drive and cardiac performance].Zeitschrift fur Gerontologie und Geriatrie · 2017Article
- Effect of non-pharmacological intervention for apathy: response to one-on-one reminiscence-based intervention.BMJ case reports · 2017Article
- Multidimensional model of apathy in older adults using partial least squares--path modeling.Age (Dordrecht, Netherlands) · 2016Article
- Agitation and Irritability in Alzheimer's Disease: Evidenced-Based Treatments and the Black-Box Warning.Current psychiatry reports · 2016Review
- Treatment and Management of Dementia Due to Alzheimer's Disease.Current treatment options in neurology · 2015Article
- The translational study of apathy-an ecological approach.Frontiers in behavioral neuroscience · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis review has evaluated the effectiveness of pharmacological treatment of apathy in patients with Alzheimer's disease (AD).
methodsA systematic literature search was conducted on published clinical trials assessing the effects of pharmacological treatment on apathy in AD over the last 10 years.
resultsFourteen studies considered of good quality were included in the analysis (4 randomized controlled trials, 9 open-label studies, and 1 retrospective analysis). Cholinesterase inhibitors were investigated in 9 studies, monoaminergic compounds such as methylphenidate and modafinil in two trials and one trial, respectively, and Ginkgo biloba (EGb 761 extract) and citalopram in one study each. Cholinesterase inhibitors did not show statistical significant effect in 1 RCT study but were associated to improvement in 3 open-label studies. Methylphenidate elicited a small but significant activity accompanied by relevant side effects such as high blood pressure, cough, and osteoarticular pain. EGb 761 was well tolerated and countered apathy. Other treatments induced modest improvements or were ineffective.
conclusionsApathy treatment remains a challenge and there is no evident advantage of any specific pharmacotherapy tested so far. The development of controlled studies according to updated guidelines for the diagnosis of apathy in patients with AD is desirable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.